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Abstract
In this work we use both model dependent and independent techniques to assess the difference between dissolution
profiles in which ibuprofen, in the form of uncoated pellets, is used as a model drug. The choice of a proper regression
function, the relevance of the estimated parameters and the influence of the choice of dissolution points in the assessment of
differences is discussed. The results obtained via mean dissolution times (MDT) and fit-factors ( f and f ) are also discussed1 2
and a non-quantitative method based on profiles correlation with graphical representation (concentration vs. concentration
and rate vs. rate) presented. The tested methods discriminate similarly between curves, although not in all cases, but those
based on modeling, MDT and fit-factors have shown to be less informative than the correlation approach.
  2003 Elsevier Science B.V. All rights reserved.
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1 . Introduction ly relevant in checking batch to batch consistency in
clinical trials, bioavailability and routine production.
In vitro dissolution has been recognized for the In the development of a new product, dissolution
past four decades as an important element both in testing can thus aid in drug release modeling, e.g.
drug development and quality assessment [1–8], through selection of excipients, optimization of the
especially in controlled release formulations. Release manufacturing process and scale-up, and formulation
and further dissolution of the drug from the solid of test products matching required dissolution
dosage forms often constitute a determining step in characteristics [9,10]. It may also be used to de-
the in vivo absorption process and is thus used in termine the long term stability of a dosage form and
conjunction with in vivo / in vitro correlations to assess the impact of post-approval changes in the
establish quality control parameters. This is especial- manufacturing process.
The methods for the comparison of dissolution
profiles may be classified into two main groups
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ANOVA-based methods [3,13] and similarity criteria for heterocedasticy, absent in previous approaches.
based on various indexes for pairwise comparison Also introduced was an additional parameter to
procedures [14–19]. It should also be pointed out describe the asymptotic value of the dissolution
that some of the methods rely on the individual profile. These changes not only increase the reliabili-
characterization of each curve (MDT, modeling), ty of the fitting parameters but drastically reduce the
while others go directly into pairwise comparison sum of squares and avoids dosage determination. We
(fit-factors and other similarity measures). MDT have also introduced a correlation approach, com-
values are strongly dependent on the upper limit of plemented with the graphical representation of pro-
the dissolution interval, while fit-factors provide files and their time variations for assessing the
exclusively a measure of absolute value discrepancy. respective differences and their evolution as dissolu-
These topics will be discussed in detail later. tion proceeds. Comparison with traditional methods,
In procedures requiring an underlying functional such as those based in fit-factors and MDT values is
form for the description of each dissolution profile, made, and their shortcomings pinpointed.
the usual approach for the determination of the
relevant parameters involves performing either or-
dinary linear (OLS) or non-linear least-squares 2 . Experimental procedure(NLLS) using a limited number of typical functions
[13,20–22]. In the case of OLS, a preliminary
2 .1. Materialslinearization step is often performed. Inspection of
residuals, weighting taking account of heterocedas-
In this work, we have used Ibuprofen (Shasun,ticy and parsimony verification are frequently absent.
batch IBU 0001097, shelf-life 12/04), as a modelThe problem is thus reduced to the comparison of
drug with pH-dependent solubility and pK of ca. 4.4aconfidence intervals for the determined fitting param- [23], microcrystalline cellulose (Microcel PH 101,eters, which requires an accurate estimation of the
Sagran, Milan, Italy), monohydrate lactose and tri-corresponding uncertainty. In most cases, modeling
calcium phosphate, as soluble and insoluble fillersdoes not contemplate estimation of the predicted
respectively, and citric acid as a pH adjuster. Sodiumasymptotic value of concentration (which is not
hydroxide and kallium dihydrogenophosphate, ana-necessarily equivalent to the total dissolved amount),
lytical grade (Merck), were used in a pH 7.260.05and results often in very poor fits. Alternative
phosphate buffer preparation. Ibuprofen solubility isprocedures for the latter task, such as the use of
increased at this pH, when compared to more acidiccalibration curves in each relevant matrix, are also
ones, which facilitates the comparison of profiles.seldom perceived and imply the independent de-
termination of the dose and batch consistency.
However, this determination has frequently broad 2 .2. Preparation of pellets
error ranges that should not be, in some cases,
introduced in assessing profile differences. The use Pellets (200 g) were prepared by the extrusion /
of qualitative (i.e. in which each profile is auto- spheronization method. Four different formulations
normalised) methods, based on correlation, may with 20% of ibuprofen were prepared as shown in
circumvent this difficulty. So, in this work we have Table 1. Demineralysed water was used as the
applied several profile comparison methods, includ- wetting liquid. The powders were mixed for 5 min
ing correlation as a non-quantitative approach, to the (Kenwood, UK) before the water was added (130
dissolution data of different uncoated pellets formu- ml). The masses were extruded in an extruder with
lations containing ibuprofen, aiming to contribute to cylinders fitted with a die of 1 mm diameter (Caleva
its evaluation and identification of eventual advan- Process, Ltd., UK). The extrudate was spheronized
tages or disadvantages. in a spheronizer (G. B. Caleva, Ltd, UK) fitted with
In summary, we have employed modeling resort- a radial plate, 250 mm diameter at 1020 rev. /min for
ing to some of the most popular functions for the 4 min. The obtained pellets were dried in a fluidized
purpose, but using weighted least squares to account bed dryer (Glatt), for 15 min at 50 8C. Pellets were
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Table 1
Pellets formulations containing 20% (w/w) of ibuprofen
I II III IV
Lactose 30.00% Lactose 25.00% Tricalcium phosphate 30.00% Tricalcium phosphate 25.00%
Microcel 50.00% Citric acid 5.00% Microcel 50.00% Citric acid 5.00%
Microcel 50.00% Microcel 50.00%
then submitted to sieve analysis using a mechanical conducted with pellets in which the active substance
sieve shaker for 10 min. is absent have shown negligible absorption in the
wavelength considered.
2 .3. In vitro dissolution studies
Dissolution of the size fraction 1.0–1.4 mm of 3 . Release modeling
each formulation was conducted in a USP Method 1
(rotating basket) apparatus, at a speed of 100 rev. / Mathematical models have been used extensively
min, in 63900 ml of dissolution media (phosphate for the parametric representation of the dissolution
buffer at pH 7.260.05), maintained at 3760.5 8C, data [3,4,13,20–22,24,25], which may be followed
using an automated assembly which consisted of a by the statistical comparison of the estimated param-
Fujitsu Ergo Proe PC, with the UV-1601PC software, eters employing a t-test. In this work we have
a peristaltic pump (Watson Marlow 205S), a UV employed several models to compare the various
spectrophotometer (Shimadzu UV-1603), a cell profiles and also attempted to identify the nature of
positioner (Shimadzu CPS-Controller), a water bath drug release. Several common models were analyzed
fitted with a variable-speed stirrer (Vankel UK 7000) (see Table 2) in a manner that slightly differs from
and a heater (Vankel VK750D). The released ibu- the most common approaches. First, when the total
profen absorbance was recorded automatically each 5 amount released is present in the regression function,
min for 8 h, at a wavelength of 264 nm. Triplicates it is used as an additional parameter. Also, non-linear
were obtained for each experiment, with a total of 18 weighted least squares, based on the Marquardt
dissolution curves for each formulation. Profile com- algorithm, was employed so as to take into consid-
parison methods were applied to the mean profile eration the heterocedastic nature of the data.
obtained from these 18 curves, which were previous- In some previous approaches, the final released
ly normalized with the pellets weighted mass. Tests amount is established from the stated dose [3,13].
Table 2
Release models tested
Zero order c t Constant release rate1
0.5Higuchi c t Fickian diffusion mechanism1
c1Korsmeyer–Peppas c t Diffusion based mechanisms2
3Hixson–Crowell c 12 12 c t Erosion release mechanisms s dd2 1
First order c 12 exp 2 c t First order mass balances s dd2 1
c2t
]Weibull c 12 exp 2 Life-time distribution functionS S D D3 c1
exp c 1 c log ts d1 2
]]]]]Logistic c 3 S-shaped model3 11 exp c 1 c log ts d1 2
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This is common practice when commercial drug obtain information that essentially describes the
products are employed. However, the value of the dominant mechanism, which is often not the same
dose may be affected with a systematic error of up to for the profiles for which a comparison is intended.
5 or 10%, depending on the substance. Having in
view the comparison of dissolution profiles, dose 3 .1. Results and discussion
errors may thus be an important part of the dis-
crepancies found. This type of error may be simply We have fitted the various functions for dissolu-
discarded if the total released amount is used as an tion times up to 60, 120 and 480 min. In the first
additional fitting parameter, which corresponds to an case, only the ascending part of the curve is consid-
extrapolation based on the prevailing mechanisms for ered, for 120 min the curves are approaching the
the period considered and thus do not necessarily plateau and 480 min correspond to the whole set of
point to the actual asymptotic value of the dissolu- points determined. In the latter case, a significant
tion profile. Its inclusion, apart from minimizing the number of points in this plateau are present in the
referred dose errors, has an additional consequence, curve (Figs. 1 and 2).
i.e. drastically improving the quality of the fit. This We first look at our results for 60 min, presented
parameter acts also as a normalising constant, and in Table 3. These indicate, based on the Akaike
should not therefore be considered in the t-test Information Criterion (AIC) [26], that the best
comparison of profiles. overall function is undoubtedly the logistic (Fig. 3),
Apart from comparing profiles, modeling may also although the Weibull function also presents good fits.
provide some insight into the drug release mecha- For formulation II, unlike the others, the best fit is
nisms. We note, however, that in some cases, a single obtained with the first order equation. The remaining
functional form is not capable of describing the functions are not adequate for the dissolution curves
whole profile. Excipients, e.g. which promote con- corresponding to our formulations (see, e.g. Fig. 4).
trolled release have an effect that tends to vary Thus, the best regression functions rely more on the
during the dissolution process. In these cases we description of shape, having not a direct connection
Fig. 1. Dissolution profiles of formulations I (a), II (b), III (c) and IV (d) fitted with the Weibull function (solid line).
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Fig. 2. As in Fig. 1 for the first order function.
with mechanism. Results for 120 min are similar to the logistic function (see Table 6 for a summary of
those reported before and stress the fact that the the t-test results) we conclude that formulations I and
logistic function is more reliable for the description III are similar, while formulation II and IV differ
of the ensemble of curves (see Table 4). These from reference I. Formulation IV differs significantly
findings are in agreement with some previous de- in both parameters for 120 min, although for 60 min
terminations, irrespective of the formulations under this difference is apparent in only one of the
study [13]. parameters. The other regression functions were not
The full curve was employed to check the predic- considered, once they fail to give a good description
tion capabilities of functions in what concerns the of the original data.
asymptotic values (see Table 5). This is relevant for When the full curve is considered, the best fit
those functions, such as the first order one, in which acordding to AIC is obtained with the Weibull
this limit is built-in. Our conclusion is that the function (Fig. 1). The correspondent t-test results
asymptotic value cannot be accurately estimated present, however, differences in one of the function
from the points corresponding to the 60 min period parameters for formulations I and III. This stems
and that a substantial deviation is found even for 120 from deviations between the fitted and the actual
min. This may be ascribed to the way in which the asymptotic dissolution values along the extended
mechanism evolves along the dissolution process as plateau.
stated before. Also, the fact that this functions do not
directly incorporate mass balance results means that
they are not capable of accurately describing the 4 . Model independent approaches
plateau value which is reached after total consump-
tion of the active substance, no matter which mecha- Model independent approaches promote direct
nism (or set of mechanisms) has been followed comparison of the dissolution data, and do not rely in
during dissolution. the choice of model functions that sometimes may
Considering thus the parameters estimated from prove artificial. The objective is essentially to trans-
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Table 3
Model parameters and AIC values for t560 min
Function Formulation c c c AIC1 2 3
23 25Zero order I 5.45310 65.74310 – – 24.81
23 25II 3.52310 65.68310 – – 7.86
23 24III 4.94310 65.51310 – – 22.75
23 25IV 7.00310 66.50310 – – 23.42
22 24Higuchi I 3.24310 63.34310 – – 8.94
22 24II 1.99310 63.35310 – – 23.27
22 24III 3.14310 63.45310 – – 9.24
22 24IV 4.28310 63.93310 – – 14.35
22 22 23Korsmeyer–Peppas I 0.5961.83310 2.4310 61.54310 – 3.1
22 23 24II 1.0263.85310 3.26310 64.64310 – 10.35
22 22 23III 0.5962.13310 2.27210 61.76310 – 6.21
22 23 23IV 0.6361.91310 6.9310 61.82310 – 8.2
22 23 23First order I 3.87310 62.42310 0.2768.81310 – 2.5
23 23 23II 1.99310 62.44310 1.8462.13310 – 25.5
22 23 23III 3.65310 62.59310 0.2769.29310 – 23.63
22 23 23IV 3.04310 62.05310 0.4061.52310 – 13.36
22 24 23Hixson-Crowell I 1.32310 66.18310 0.2465.90310 – 6.37
23 23 23II 1.02310 61.14310 1.2161.29310 – 10.25
22 24 23III 1.25310 66.56310 0.2465.94310 – 2.61
22 24 23IV 1.10310 65.60310 0.3569.76310 – 23.8
22 22Weibull I 43.9615.65 0.8167.09310 0.3565.98310 210.72
22II 35.263.69 1.5960.13 0.2161.75310 21.31
22 22III 33.267.677 0.9168.11310 0.3063.32310 24.32
22 22IV 34.966.21 0.9767.12310 0.4263.93310 212.10
22Logistic I 23.4860.11 0.8769.58310 0.4960.11 212.29
22II 26.3360.42 1.7860.19 0.2763.32310 25.09
22III 23.5860.14 1.0160.12 0.3966.10310 26.26
22IV 23.8860.13 1.0660.10 0.5567.55310 218.50
late either the profile or profile differences into a where the denominator corresponds to the total
single value. amount dissolved, M(`). A fraction of drug release,
M(t) /M(`) is related to the number of molecules of
drug substance released from the dosage form up to4 .1. Moments of the dissolution profiles
the time t and can be regarded as a cumulative
function F(t) in the statistical sense [12]. In practice,The mean in vitro dissolution times (MDT) are
the integrals in the above equation are computedgiven from a release M(t) by [2]
numerically, yielding,
`
¯E t dM(t) O t DMi i
i0 ]]]MDT5 (2)]]]MDT5 (1)` O DMi
iE dM(t)
¯where t is the midpoint of the time period during0 i
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Fig. 3. Dissolution profiles up to 60 min fitted with the Logistic function (solid line).
Fig. 4. As in Fig. 3 for the Hixson–Crowell function.
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Table 4
Model parameters and AIC values for t5120 min
Function Formulation c c c AIC1 2 3
23 25Zero order I 4.02310 63.26310 – – 52.85
23 25II 2.93310 62.86310 – – 29.8
23 25III 3.62310 62.75310 – – 50.66
23 25IV 4.97310 63.17310 – – 56.31
22 24Higuchi I 3.23310 62.51310 – – 7.55
22 24II 2.33310 62.31310 – – 40.68
22 24III 3.11310 62.29310 – – 8.87
22 24IV 4.22310 62.60310 – – 19.87
23 23 23Korsmeyer–Peppas I 0.5361.09310 2.90310 61.25310 – 7.49
23 23 24II 0.8061.78310 6.89310 65.20310 – 22.32
23 23 23III 0.5261.20310 2.92310 61.46310 – 10.86
23 23 23IV 0.5269.95310 3.93310 61.61310 – 21.96
23 24 23First order I 2.78310 2.75310 0.4261.76310 – 11.72
23 24 23II 9.94310 68.43310 0.42.50310 – 11.48
23 23 23III 2.63310 61.05310 0.3265.56310 – 7.55
23 24 23IV 2.62310 8.34310 0.4666.29310 – 29.03
23 24 23Hixson–Crowell I 8.84310 62.47310 0.3164.34310 – 21.24
23 24 23II 4.12310 62.80310 0.3461.55310 – 10.33
23 24 23III 8.24310 62.38310 0.3063.89310 – 18.06
23 24 23IV 8.42310 61.95310 0.4164.31310 – 11.07
23 23Weibull I 67.5614.19 0.7563.98310 0.4363.88310 225.10
23 23II 55.563.80 1.2965.92310 0.3061.26310 20.29
23 23III 58.8610.04 0.7864.40310 0.3962.84310 211.55
23 23IV 43.563.36 0.9163.83310 0.4761.61310 224.03
23 23 23Logistic I 23.5666.61310 0.8165.44310 0.5967.38310 231.29
23 23II 25.8560.23 1.4868.88310 0.3762.32310 27.09
23 23 23III 23.6068.75310 0.8766.24310 0.5165.19310 216.35
23 23IV 23.8760.11 1.0465.82310 0.5863.13310 244.64
which the fraction DM of the drug as been released ated with the MDT (VT) [12]. An additional advan-i
from the dosage form [2]. Other similar formula tage is that Eqs. (1)–(3) are self-normalized, i.e. they
gives the moments of dissolution times of order k are amenable to direct treatment of signal data. The
method may require, however, the knowledge of the
k
¯O t DM time at which the plateau, i.e. full dissolution, isi i
i
]]]m 5 (3) attained (see below).k O DMi Variance of dissolution times are estimated from
i
2
¯O(t 2MDT) DMOne of the advantages of this method is that the i i
i
]]]]]]comparison is based on a physically significant VT5 (4)O DMiquantity, of widespread use for establishing in vitro /
iin vivo correlations. It is also possible to characterize
the profiles with statistical moments such as MDT, The relative dispersion of dissolution times (RD) is
its relative dispersion (RD) and the variance associ- given by [27]
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Table 5
Model parameters and AIC values for t5480 min
Function Formulation c c c AIC1 2 3
23 25Zero order I 1.36310 63.26310 – – 244.03
23 26II 1.33310 66.19310 – – 205.83
23 26III 1.55310 67.89310 – – 229.26
23 26IV 1.51310 66.13310 – – 260.92
23 24Higuchi I 2.50310 61.20310 – – 157.13
23 24II 2.29310 61.04310 – – 112.93
23 25III 2.61310 68.67310 – – 126.97
23 24IV 2.88310 61.00310 – – 191.00
23 23 23Korsmeyer–Peppas I 0.3563.75310 5.7310 61.15310 – 114.06
23 23 24II 0.5065.42310 2.34310 66.86310 – 115.4
23 23 23III 0.3664.88310 5.34310 61.32310 – 80.91
23 23 23IV 0.2763.58310 9.96310 61.87310 – 134.23
23 24 23First order I 1.78310 62.74310 0.4261.76310 – 36.17
23 24 23II 1.00310 61.92310 0.4263.02310 – 231.44
23 24 23III 1.70310 63.22310 0.4062.27310 – 28.43
23 24 23IV 2.42310 63.85310 0.4661.98310 – 280.62
23 25 23Hixson–Crowell I 3.38310 63.04310 0.4262.09310 – 137.59
23 25 23II 3.13310 64.72310 0.3962.75310 – 8.78
23 25 23III 3.55310 63.93310 0.4162.93310 – 113.13
23 25 23IV 3.44310 62.82310 0.4962.61310 – 174.57
23 23Weibull I 65.161.76 0.7961.57310 0.4363.14310 250.44
23 23II 98.162.41 1.0262.05310 0.4263.83310 229.94
23 23III 72.562.87 0.7661.90310 0.4365.66310 289.12
23 23IV 42.160.76 0.9362.07310 0.4662.26310 2142.36
23 23 23Logistic I 23.8067.38310 0.9762.62310 0.4966.77310 22.60
23 23II 25.4860.12 1.2663.38310 0.4767.20310 267.27
23 23 23III 23.7168.44310 0.9163.09310 0.5061.12310 260.4
23 23IV 24.3660.11 1.2963.59310 0.4863.64310 232.92
some problems. For zero order (or close to zeroVT
]]RD5 (5) order) release mechanisms, Eq. (1) yields, in prac-2MDT 1
]tice, MDT5 t when infinite dissolution timesmax2
In spite of the mentioned advantages, the use of are replaced by specific dissolution intervals between
mean dissolution times (or similar approaches) poses 0 and t . This means that when such curves aremax
Table 6
Results of the comparison of formulation I with test curves from modeling functions (t-test, a 5 0.05). Indicated is when difference is found
for only one parameter
Formulation Logistic (t560 min) Logistic (t5120 min) Weibull (t5480 min)
II Different Different Different
III Similar Similar Different (1 parameter)
IV Different (1 parameter) Different Different
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truncated before full dissolution, the result is in-
dependent of the release rate, rendering impossible
the discrimination between two curves. Of course,
for other release mechanisms differences may arise,
but the dependence on the upper integration limit is
always present.
4 .2. Results and discussion
Results obtained from our formulations are shown
in Table 7, for t5 60, 120, and 480 min. With the
obtained RD values it is not possible to conclude
about release order or, more generally, mechanism,
by comparison to those obtained for some common Fig. 5. MDT values for formulations I, II, III and IV at different
cumulative time points.models (see description in Ref. [12]). This fact
suggests the coexistence of different mechanisms.
MDT values, naturally, tend to increase with time. that uses a difference factor ( f ) and a similarity1
The increase is much more evident when the formu- factor ( f ) was proposed to compare dissolution2
lation has some prolonged release as we can see with profiles [14]. Fit factors were adopted by FDA
formulation II when compared to the reference Center for Drug Evaluation and Research (CDER)
(formulation I). The MDT value of formulation IV at and the similarity factor was also adopted by the
t5 60 min is higher than that of the reference which European Medicines Evaluation Agency (EMEA)
reflects a lower dissolution rate, but this effect is lost Committee for Proprietary Medicinal Products
and the dissolution of this formulation reaches the (CPMP) as an assessment criterion of similarity
lowest MDT value, showing a modification in re- between two in-vitro dissolution profiles [9,10]. The
lease rate or dissolution mechanism. Also, we see difference factor ( f ) calculates the percent differ-1
that these values are stable even when the plateau is ence between the two curves at each time point and
taken into consideration, which allows for a charac- is a measure of the relative error between the two
terization of the complete dissolution curve [12]. curves,
These findings are also illustrated in Fig. 5. This
n
method, for our data, indicates the extension of an O R 2Tu ut tinduced controlled release effect even when it is t51
]]]]f 5 3 100 (6)1observed for a very short period of time, which is O Rt
very useful in formula development and comparison
of excipients. where n is the number of time points, R is thet
dissolution value of the reference formulation at time
4 .3. Fit factors t and T is the dissolution value of the test formula-t
tion at time t.
Recently a simple model independent approach The similarity factor ( f ) is a logarithmic re-2
Table 7
MDT and VT values for formulations I, II, III and IV at t560, 120 and 480 min (number of points considered n513, 25 and 97,
respectively)
60 min 120 min 480 min
I II III IV I II III IV I II III IV
MDT/min 19.89 25.89 18.79 21.38 35.81 44.58 34.56 34.5 59.79 93.42 63.57 45.52
2VT/min 1041 1256 988.9 768.4 3036 3469 3090 2119 8567 18684 11476 7265
RD 2.631 1.874 2.801 1.681 2.368 1.746 2.587 1.780 2.396 2.141 2.840 3.506
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ciprocal square root transformation of the sum of they present a great advantage of reducing complexi-
squared error and is a measurement of the similarity ty by providing a single number to describe two
in the percent (%) dissolution between the curves curves that consist of several points [14].
Results obtained from our formulations are shownn 20.51
2 in Table 8. The recommendations presented in the]f 5 50 log 11 O R 2T 3 100s dHF G J2 t tn t51 above mentioned guidelines were followed and we
observe that the similarity factor f is more sensitive(7) 2
in finding dissimilarity between dissolution curves
than the difference factor f and, also, that theseFor curves to be considered similar, f values 11
values are dependent on the length of dissolutionshould be close to 0 and f values should be close to2
profile and number of time points chosen. These100. Generally, f values up to 15 (0–15) and f1 2
findings have been also mentioned by other authorsvalues greater than 50 (50–100), which means an
[13,15]. Our results show clear differences betweenaverage difference of no more than 10% at the
formulations I and II and a similitude between I andsample time points [16], ensures equivalence of the
III. In what concerns formulations I and IV thetwo curves and thus of the performance of the test
difference appears for the largest dissolution intervaland reference products [10].
considered (120 min). This might indicate that aFit factors are essentially a quantitative method,
large number of time points should be included inreflecting the differences between corresponding
order to obtain a suitable discrimination.values in the two curves. They do not indicate the
sense of the deviation, and yield the same value
4 .4. Correlation coefficients and similarity criteriairrespectively of the test curve being placed below or
above the reference [14]. Thus, they do not directly
In cluster analysis [28] euclidean distances (andtake into consideration the shape of the curve, and
their variants) and correlation coefficients are fre-not allow for a variation in the spacing between
quently used as measures of similarity. These mea-sampling times [19,25]. Also, they do not take into
sures can be applied in a straightforward manner toaccount variability within test and references bat-
dissolution curves. The use of euclidean distancesches. Since fit factors are commulative functions
would have the same underlying philosophy as thethey are sensitive to measurements obtained after
use of fit-factors, also consisting of an essentiallyeither test or reference batch are dissolved more than
quantitative approach. The use of correlation co-85% [16]. Thus it becomes apparent that the selec-
efficients in the comparison focus, for our analysis,tion and determination of the dissolution end pull
on the shape of the curves, discarding the absolutepoints plays a critical role in the calculation of fit
value. It is thus, a valuable complement of somefactors and the subsequent decision as to whether the
other approaches.test and reference profiles resemble each other or not
The correlation coefficient (r) measures the[13,15].
strength of the linear relationship between twoIn spite of these limitations fit-factors have been
variables, say X and Y:very useful in comparing dissolution curves once
Table 8
Fit factors values for formulations II, III and IV compared with formulation I
Fit factors t510, 40 and 120 min up to t530 min up to t560 min up to t5120 min
aI / II I / III I / IV I / II I / III I / IV I / II I / III I / IV I / II I / III I / IV
f 3.96 0.57 2.41 8.65 0.65 2.6 13.6 1.19 6.57 26.4 2.29 9.631
f 42.6 88.0 50.4 42.2 92.6 63.9 42.2 87.2 52.1 43.4 86.5 48.62
For the second heading, only the three points indicated have been considered, while in the remaining, and except where noted, all
determined points have been included.
a Dissolution curve of formulation IV without time points from 90 to 115 min.
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] ]O x2x y2ys ds d
]]]]]]r5 (8)]]]]]]
] ]2 2O x2x O y2ys d s dœ
] ]where x and y are the variables points and x and y
are the respective means. Correlation coefficient
ranges from 21 to 11. For r 561 there exists a
functional relationship between X and Y and all
points (x, y) lie on a straight line. If r 5 0 then X and
Y are uncorrelated; two random variables are the
more strongly correlated the closer r is to 1 [29].u u
4 .4.1. Graphical representation
The use of correlation coefficients suggests the Fig. 7. Graphical representation of test formulations II, III and IV
concomitant use of concentration vs. concentration normalized absorvance signal as a function of that of formulation I
or rate vs. rate plots. In fact, the linearity of these (reference). Correlation coefficients (t5480 min) also shown.
plots corresponds, using this criterium, to a high
similitude between curves. These plots also provide efficients clearly present a high degree of similitude
information concerning the relative evolution of for formulation III and the reference that decreases
profiles and, for complete dissolution curves, pin- slightly for formulation IV and again, more marked-
point the times for which dissolution has come to a ly, for formulation II. This picture is present up to
halt in certain formulation while continues in others. ca. 120 min, where a substantial portion the active
substance is already in solution, and inverts for
4 .4.2. Discussion formulation II and IV when a large number of points
Our results are based on correlation coefficients in the asymptotic plateau is included. We note that,
calculated both from the normalized signals and the for our data, the choice of time at which the curve is
corresponding rates, respectively presented in Fig. 6 truncated becomes irrelevant with rate coefficients.
panels (a) and (b). While rate based coefficients In what concerns the concentration plots, Fig. 7,
emphasize differences, those related to concentration we see that the formulation IV is the first to attain
show the commulative behavior of the dissolution complete dissolution, while formulation II is the
profiles, which is also shown in Fig. 7. Both co- slowest. It also patent the similitude between formu-
lation I and III. We may also observe that the bulk
concentration for formulation II is always below that
of the other curves. For formulation IV, a slower start
is compensated by an intermediate increase.
The rate vs. rate plots, Fig. 8, depict similar
conclusions. The effects in the beginning of the
curves are much more emphasized, due to drastic
initial variations and in spite of our constant interval
between time points. The initial zero order release
present for formulation II is clearly represented as is
the initially slow behavior of formulation IV and its
subsequent increase.
5 . Final remarksFig. 6. Correlation coefficients between formulations pairs (refer-
ence / test) I / II, I / III and I / IV normalized absorvance signal (a)
and respective time derivatives (b). All methods considered here have given results
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corresponding graphical representation provides a
useful way to emphasize non-quantitative differ-
ences, and their evolution along the profile. How-
ever, they lack a simple criterion for classification
into ‘similar’ or ‘different’.
In our view, the combination of fit-factors, in a
quantitative perspective, with correlation coefficients,
for spotting shape differences, provides a reliable
way to assess differences between profiles.
If one is interested in an in-depth analysis of the
release-control factors, the time extension of their
action and its sense, then suitable graphical repre-
sentations, such as those suggested here, should also
be taken into consideration.Fig. 8. Graphical representation of test formulations II, III and IV
normalized signal time derivative as a function of the corre-
sponding values for the reference. Correlation coefficients (t5480
min) are also shown.
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